ArticleJournal of veterinary pharmacology and therapeutics2025
Pharmacokinetics of Single Dose and Multidose Oral Gabapentin in Goats (Capra aegagrus hircus).
Article in Journal of veterinary pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is a shifting public perception of animal welfare that has increased demand for establishing pain management strategies in livestock. Gabapentin is often utilized in practice to mitigate neuropathic pain. However, there is little pharmacokinetic information to guide its use in goats. The objectives of this study were to describe the pharmacokinetics of oral gabapentin in goats given as a single dose (SD) and multidose (MD) regimen, as well as to document any adverse effects after administration. Six healthy adult goats were administered 15 mg/kg of gabapentin orally once for the SD trial, and every 12 h for 6 doses for the MD trial. Plasma samples were collected and analyzed via reversed-phase high-performance liquid chromatography. After SD administration, maximum plasma concentration, time to maximum concentration, and elimination half-life were: 3.22 μg/mL; 4.49 h; and 8.15 h, respectively. After MD administration, maximum plasma concentration and time to maximum concentration were: 4.56 μg/mL and 2.24 h. Accumulation ratio (R) was 1.66 ± 0.81 when comparing the MD AUC12
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.